BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...at Allergan Inc., where he led worldwide strategy and BD for the company’s medical aesthetics unit.Precirix...
...investment opportunities and creates new ventures. Nowicki identifies new public and private investment opportunities. BC Staff Arcutis Editas Medicine PRECIRIX frazier...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...therapy in preclinical testing for prostate cancer.Belgian radiopharmaceutical company Precirix...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...INKEF Capital , Roche Venture Fund , Novo Seeds , Lundbeckfond Emerge Preclin Neurology 2016 Camel-IDS...
BioCentury | Nov 16, 2018
Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

...Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A...
...led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners. Camel-IDS...
...radiolabeled camelid single-domain antibody targeting HER2, can enter brain lesions unlike mAbs. Earlier this year, Camel-IDS...
BioCentury | Nov 16, 2018
Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

...Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A...
...led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners. Camel-IDS...
...Morten Graugaard Døssing from Novo Seeds and Ohad Hammer from Pontifax. Camel-IDS N.V., Brussels, Belgium Mark Zipkin CAM-H2 Camel-IDS...
BioCentury | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

...He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS...
Items per page:
1 - 6 of 6
BioCentury | Jan 12, 2021
Management Tracks

Editas shares sink as CSO Albright readies to depart; plus Arcutis, Precirix, Frazier

...at Allergan Inc., where he led worldwide strategy and BD for the company’s medical aesthetics unit.Precirix...
...investment opportunities and creates new ventures. Nowicki identifies new public and private investment opportunities. BC Staff Arcutis Editas Medicine PRECIRIX frazier...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...therapy in preclinical testing for prostate cancer.Belgian radiopharmaceutical company Precirix...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...INKEF Capital , Roche Venture Fund , Novo Seeds , Lundbeckfond Emerge Preclin Neurology 2016 Camel-IDS...
BioCentury | Nov 16, 2018
Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

...Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A...
...led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners. Camel-IDS...
...radiolabeled camelid single-domain antibody targeting HER2, can enter brain lesions unlike mAbs. Earlier this year, Camel-IDS...
BioCentury | Nov 16, 2018
Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

...Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A...
...led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners. Camel-IDS...
...Morten Graugaard Døssing from Novo Seeds and Ohad Hammer from Pontifax. Camel-IDS N.V., Brussels, Belgium Mark Zipkin CAM-H2 Camel-IDS...
BioCentury | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

...He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS...
Items per page:
1 - 6 of 6